We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Creo Medical Group Plc | LSE:CREO | London | Ordinary Share | GB00BZ1BLL44 | ORD GBP0.001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 34.75 | 34.50 | 35.00 | 34.75 | 34.75 | 34.75 | 216,151 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Surgical,med Instr,apparatus | 27.17M | -26.94M | -0.0746 | -4.66 | 125.53M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/11/2019 13:42 | Inverse H&S nearly complete (210) - then where? | toffeeman | |
12/11/2019 13:33 | Back in the 2's .. sweet. | dplewis1 | |
12/11/2019 12:06 | Yes. Be nice to get past those spiky highs | volsung | |
12/11/2019 09:28 | A hidden gem. imo | hazl | |
11/11/2019 19:01 | Decent buying again. Getting back above 2 quid would be good.. | dplewis1 | |
08/11/2019 11:46 | ....from memory news expected before the end of the year....a flurry of buying always interesting. | hazl | |
07/11/2019 15:54 | Bought a few more for the SIPP. Av now 188.04p | volsung | |
05/11/2019 15:37 | I reckon we might get an RNS on that likely purchase! Hope so. | hazl | |
05/11/2019 13:29 | Well there's confidence for you! A trade at 196852....could be from yesterday? Thoughts? | hazl | |
05/11/2019 09:57 | It's stayed up so I imagine there must be a buy in the background. | hazl | |
31/10/2019 08:17 | They say good things come to those that wait....hope so! | hazl | |
28/10/2019 19:01 | Craig Gulliford 'The full commercial launch of the Speedboat device, coupled with the opportunity to show-case the wider suite of products at this key event, is another important step for the Company. In addition to the profiling of our technology in the exhibition area, we will also be using the time together with our distribution partners throughout Europe to outline the initial roll out plans for the wider portfolio and use this fantastic opportunity to build further excitement and momentum as we head into 2020." | hazl | |
28/10/2019 19:01 | If you have any doubts,just read the excellent header above that is continuously updated....thanks Pecuniarum. | hazl | |
25/10/2019 09:06 | 2019 was mentioned as hopeful and certainly the products previously were put through in ultra quick time which bodes well. IMO | hazl | |
25/10/2019 09:00 | I think it will get a boost when the further products have FDA clearance. | hazl | |
24/10/2019 16:05 | Cheers hazl | volsung | |
24/10/2019 15:56 | Hi volsung welcome! | hazl | |
24/10/2019 15:49 | Topsliced my SLN and bought an initial tranche here. Interesting prospect | volsung | |
24/10/2019 15:18 | Ah here we have it back in September they state..... 'Furthermore, we added to our agreement with Hoya Group, Pentax Medical with a European framework distribution agreement covering France, Germany and Italy. In the period we had two successful FDA pre sub meetings and remain on track for a suite of cleared GI products during 2019. We continue to invest in our pipeline, positioning us well to become a leading advanced energy, minimally invasive, medical device company." 'we remain on track for a suite of cleared products during 2019'....that bodes well for more announcements! Can't wait! | hazl | |
24/10/2019 10:06 | Hmm a '1' TRADE.... | hazl | |
24/10/2019 08:52 | AND we have more awaiting clearance! | hazl | |
24/10/2019 08:51 | What a good sign that was above! | hazl | |
24/10/2019 08:50 | 'Creo Medical Group out of Chepstow in South Wales won clearance from the FDA for its Speedboat RS2 device and CROMA platform for endoscopic removal of cancerous and pre-cancerous lesions in the bowel.' 'This was one of the fastest FDA reviews of a 510(k) cleared medical device to date, with the company receiving the answer 49 days following submission of the request. The clearance was so unexpectedly expedient that Creo is now having to adjust its commercialization plans in the U.S. to bring the product to market earlier.' | hazl |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions